Tom Wilemon

August 15, 2019

Potential second-line melanoma treatment identified

A study led by Anna Vilgelm, MD, PhD, and Ann Richmond, PhD, has identified a possible second-line treatment for melanoma patients.

By Tom Wilemon
August 15, 2019

Protein’s role in inflammation-related cancer studied

Investigators are exploring the molecular mechanisms behind the association of chronic inflammation and colon cancer.

By Tom Wilemon
August 7, 2019

Colorectal cancer patients warn against dismissing early symptoms

Younger patients say colorectal cancer is a disease that doesn’t follow age guidelines, so pay attention to early symptoms.

By Tom Wilemon
August 1, 2019

Shu, Zheng receive Vietnam’s top honor for foreign scientists

The Vietnamese Ministry of Health has awarded two Vanderbilt epidemiologists the Memorabilia Medal “For the People’s Health” in appreciation for their contributions in helping the nation establish a population-based research program for cancer, diabetes and other non-communicable diseases.

By Tom Wilemon
August 1, 2019

Grant bolsters research on myelodysplastic syndromes

Michael Savona, MD, has received a competitive grant to develop therapies for patients with myelodysplastic syndromes.

By Tom Wilemon
July 22, 2019

Encephalitis identified as rare toxicity of immunotherapy treatment

Researchers are chronicling rare but serious toxicities that may occur with immune checkpoint inhibitors, the most widely prescribed class of immunotherapies.

By Tom Wilemon
July 18, 2019

Center for Immunobiology grows, bolsters program

The Vanderbilt Center for Immunobiology has relaunched its mission with a greater focus on human immunology, an endeavor supported by additional researchers, more funding support and designation as a Center of Excellence.
By Tom Wilemon
June 26, 2019

Biomarkers of DNA methylation can be a predictor of breast cancer risk

Biomarkers of DNA methylation, which regulate gene expression, can be a predictor of breast cancer risk.
By Tom Wilemon
June 18, 2019

Study identifies critical regulator of tumor-specific T cell differentiation

A study published June 17 in Nature offers clues as to why blocking inhibitory receptors on tumor-infiltrating T cells may not always work
By Tom Wilemon
June 13, 2019

Cardiac toxicity risk factors identified with relapsed multiple myeloma therapy

More than half of patients with relapsed multiple myeloma treated with carfilzomib experienced cardiac issues during treatment, according to a multi-institutional study published June 12 in the Journal of Clinical Oncology.
By Tom Wilemon
June 13, 2019

Eng named to GI cancer leadership position at VICC

Cathy Eng, MD, a national and international leader in gastrointestinal medical oncology, is joining Vanderbilt-Ingram Cancer Center (VICC).
By Tom Wilemon
June 13, 2019

Treatment approved for patients with acute graft-versus-host disease

The U.S. Food and Drug Administration (FDA) recently approved ruxolitinib, the first drug for patients with acute graft-versus-host disease (GVHD) who have an inadequate response to steroid treatment. VUMC's Madan Jagasia, MBBS, MS, MMHC, was a lead investigator of the REACH1 trial that was the basis for the FDA approval.
By Tom Wilemon
1 … 23 24 25 26 27 … 39